The burden of headache disorders in the adult population of Morocco: estimates, and a health-care needs assessment, from a cross-sectional population-based door-to-door survey.

Background: We have previously shown headache disorders to be prevalent in in the adult general population of Morocco, especially migraine (30.8%) and headache on ≥ 15 days/month (H15+; 10.5%).

Influence of antiplatelet medication and anticoagulation therapy after dental extractions on hospitalization: a retrospective 10-year study.

Background: The aim of this retrospective study was to identify high-risk dental extraction patients and the timing of postoperative hemorrhage to evaluate whether preventive hospitalization should be considered in patients on antiplatelet medication (AP) or anticoagulants.

Methods: Our study included 1595 procedures; 1319 were conducted under monotherapy (Group I: AP; Group II: indirect oral anticoagulant [IAC]; Group III: direct oral anticoagulant [DOAC]) and 276 under dual therapy (Group IV: double AP; Group V: AP and IAC; Group VI: AP and DOAC). We evaluated the incidence, frequency and timing of hemorrhage, hospitalization rate, and treatment of bleeding incidents.

The burden of headache disorders among adults in Peru: national estimates and a health-care needs assessment from a population-based door-to-door survey.

Background: We have previously found that almost two thirds (64.6%) of adults in Peru have an active headache disorder. Here, using data from the same sample, we present attributed burden at individual and population levels.

Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.

Background: No treatment is available to prevent brain oedema, which can occur after a large hemispheric infarction. Glibenclamide has previously been shown to improve functional outcome and reduce neurological or oedema-related death in patients younger than 70 years who were at risk of brain oedema after an acute ischaemic stroke. We aimed to assess whether intravenous glibenclamide could improve functional outcome at 90 days in patients with large hemispheric infarction.

, a new genus of Dorvilleidae (Annelida) from deep waters of the Southwest Atlantic Ocean and an insight into its relationship within the family.

Dorvilleidae Chamberlin, 1919 is a family of Annelida containing some of the smallest 'polychaetes' species, being poorly studied worldwide, and with little knowledge regarding its diversity and occurrence. Samples obtained in oceanographic campaigns performed in the Southwest Atlantic Ocean (Brazilian coast) revealed a high number of specimens of dorvilleids, adding to our knowledge of the family's biodiversity. A detailed morphological analysis of these organisms has revealed a new genus, , with two new species.